摘要
前列腺癌是威胁中老年男性生命健康的最常见的恶性肿瘤之一,其死亡率仅次于肺癌。前列腺特异性膜抗原(prostatic specific membrane antigen,PSMA)是一种前列腺癌细胞高表达的跨膜蛋白,是前列腺癌早期诊断、分期和治疗中的重要靶点。基于此,放射性核素标记的PSMA成为正电子发射型计算机断层显像(positron emission tomography,PET)的靶向分子探针,在前列腺癌患者的诊疗中具有独特的优势和重要的价值。本文总结了PSMA PET在前列腺癌临床诊疗中的应用进展,旨在更好服务于临床。
Prostate cancer is the most common malignant tumor that threatens the health of middle-aged and elderly men,and the second leading cause of cancer death,only lower than lung cancer.Prostate-specific membrane antigen (PSMA) is a transmembrane protein overexpressed by prostate cancer cells,and it has become an important target for early diagnosis,staging and treatment of prostate cancer.Based on it,radionuclide-labeled PSMA is promising to serve as a potent biomarker for positron emission tomography (PET) imaging.Besides,it plays a unique and important role in the diagnosis and treatment of prostate cancer.This article summarizes the clinical value of PSMA-PET in the diagnosis and treatment of prostate cancer,and aims to provide evidences for clinical diagnosis and treatment.
作者
宁静
刘亚超
徐白萱
NING Jing;LIU Yachao;XU Baixuan(Chinese PLA Medical School,Beijing 100853,China;Department of Nuclear Medicine,the First Medical Center,Chinese PLA General Hospital,Beijing 100853,China)
出处
《解放军医学院学报》
CAS
2020年第1期88-91,共4页
Academic Journal of Chinese PLA Medical School
基金
国家自然科学基金项目(81571715).
